HCV
MCID: HPT073
MIFTS: 67

Hepatitis C Virus (HCV)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis C Virus

MalaCards integrated aliases for Hepatitis C Virus:

Name: Hepatitis C Virus 57
Hepatitis C Virus, Susceptibility to 57 29 6 40
Hepatitis C Virus Infection, Response to Therapy of 57 29 6
Response to Antiviral Treatment in Hepatitis C 59
Hepatitis C Virus, Response to Therapy of 57
Response to Peg/ifn-Ribavirin in Hcv 59
Hepatitis C Virus, Resistance to 57
Resistance to Hepatitis C Virus 6
Hcv, Susceptibility to 57
Hcv 57

Classifications:



External Ids:

OMIM 57 609532
Orphanet 59 ORPHA284102

Summaries for Hepatitis C Virus

OMIM : 57 HCV, which is principally transmitted by blood, infects about 3% of the world's population. HCV infection causes acute hepatitis, which is self-resolving in 20 to 50% of cases but does not confer permanent immunity. In 50 to 80% of cases, HCV infection becomes chronic and results in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. As a result, HCV infection is a leading killer worldwide and the most common cause of liver failure in the U.S. HCV is opportunistic in individuals infected with human immunodeficiency virus (HIV; see 609423), approximately 25% of whom are coinfected with HCV. HCV infection is also associated with cryoglobulinemia (see 123550), a B-lymphocyte proliferative disorder (Pawlotsky, 2004; Chisari (2005); Pileri et al., 1998). (609532)

MalaCards based summary : Hepatitis C Virus, also known as hepatitis c virus, susceptibility to, is related to hepatitis c and hepatitis. An important gene associated with Hepatitis C Virus is IFNG (Interferon Gamma), and among its related pathways/superpathways are JAK-STAT signaling pathway (KEGG) and Blood-Brain Barrier Pathway: Anatomy. The drugs Tacrolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and b cells, and related phenotypes are Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and hematopoietic system

Wikipedia : 76 Hepatitis C virus (HCV) is a small (55�??65 nm in size), enveloped, positive-sense single-stranded RNA... more...

Related Diseases for Hepatitis C Virus

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis C Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 520)
# Related Disease Score Top Affiliating Genes
1 hepatitis c 33.5 CD81 CLDN1 CLDN6 CLDN9 CLEC4M GPT
2 hepatitis 32.7 CD81 CLDN1 CLDN6 CLDN9 GPT IFNL4
3 viral infectious disease 32.4 CCR5 CD81 GPT IFNG
4 hepatitis d 30.8 GPT IFNL3
5 cryptogenic cirrhosis 30.6 KRT18 KRT8
6 nonalcoholic steatohepatitis 30.4 GPT KRT18
7 recurrent hepatitis c virus induced liver disease in liver transplant recipients 12.3
8 hepatocellular carcinoma 11.8
9 polyarteritis nodosa 11.5
10 fibrillary glomerulonephritis 11.2
11 immunotactoid glomerulopathy 11.2
12 immunotactoid or fibrillary glomerulopathy 11.2
13 noonan syndrome 3 11.0
14 cryoglobulinemia 10.9
15 cryoglobulinemia, familial mixed 10.8
16 hepatitis b 10.8
17 liver disease 10.7
18 glomerulonephritis 10.7
19 liver cirrhosis 10.7
20 lymphoma 10.6
21 noonan syndrome 2 10.6
22 vasculitis 10.6
23 membranoproliferative glomerulonephritis 10.6
24 porphyria cutanea tarda 10.5
25 porphyria 10.5
26 lichen planus 10.5
27 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.4
28 oral lichen planus 10.4
29 autoimmune lymphoproliferative syndrome, type v 10.4
30 b-cell lymphomas 10.4
31 kidney disease 10.4
32 lymphoproliferative syndrome 10.4
33 noonan syndrome 5 10.4
34 chronic kidney failure 10.4
35 neurenteric cyst 10.4 KRT18 KRT8
36 human immunodeficiency virus type 1 10.3
37 thalassemia 10.3
38 proliferating trichilemmal cyst 10.3 KRT18 KRT8
39 cutaneous adenocystic carcinoma 10.3 KRT18 KRT8
40 noonan syndrome 4 10.3
41 polyarteritis nodosa, childhood-onset 10.3
42 cervical clear cell adenocarcinoma 10.3 KRT18 KRT8
43 odontoma 10.3 KRT18 KRT8
44 fatty liver disease, nonalcoholic 1 10.3
45 arthritis 10.3
46 hemophilia 10.3
47 purpura 10.3
48 type ii mixed cryoglobulinemia 10.3
49 mucinous tubular and spindle renal cell carcinoma 10.3 KRT18 KRT8
50 cholangiocarcinoma 10.2

Graphical network of the top 20 diseases related to Hepatitis C Virus:



Diseases related to Hepatitis C Virus

Symptoms & Phenotypes for Hepatitis C Virus

Clinical features from OMIM:

609532

GenomeRNAi Phenotypes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 9.02 CD81 CLDN1 GPT HM13 PNKD

MGI Mouse Phenotypes related to Hepatitis C Virus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 ATG5 CCR5 CD81 CLEC4M HM13 IFNG
2 immune system MP:0005387 9.65 ATG5 CCR5 CD81 CLEC4M HM13 IFNG
3 liver/biliary system MP:0005370 9.23 ATG5 CCR5 HM13 IFNG KRT18 KRT8

Drugs & Therapeutics for Hepatitis C Virus

Drugs for Hepatitis C Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 612)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
4
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
5
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
6
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
7
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
8
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 99210-65-8, 215647-85-1
9
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
10
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
11
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
12
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
13
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
14
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 143491-57-0 60877
15
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
16
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
17
leucovorin Approved Phase 4,Phase 2,Phase 1 58-05-9 6006 143
18
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
19
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1256388-51-8 67505836
20
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1190307-88-0 45375808
21
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6
22
Insulin glulisine Approved Phase 4 207748-29-6
23
Insulin Glargine Approved Phase 4 160337-95-1
24
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3 142217-69-4 153941
25
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 923604-59-5 66576988
26
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
27
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
28
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
29
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 46835353 6436030 5284616
30 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
32
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 154598-52-4 64139
33
Zidovudine Approved Phase 4,Phase 1,Phase 2 30516-87-1 35370
34
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 134678-17-4 60825
35
Interferon alfacon-1 Approved, Investigational Phase 4,Phase 3,Phase 2 118390-30-0 9554198
36
Nevirapine Approved Phase 4 129618-40-2 4463
37
Rifaximin Approved, Investigational Phase 4,Phase 2,Not Applicable 80621-81-4 6436173
38
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 192725-17-0 92727
39
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 152923-56-3, 179045-86-4
40
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 1 376348-65-1 3002977
41
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
42
Armodafinil Approved, Investigational Phase 4 112111-43-0
43
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
44
Cobicistat Approved Phase 4,Phase 3,Phase 1 1004316-88-4
45
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
46
Losartan Approved Phase 4 114798-26-4 3961
47
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925
48
Nelfinavir Approved Phase 4 159989-64-7 64143
49
Orlistat Approved, Investigational Phase 4,Not Applicable 96829-58-2 3034010
50
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 40400 644073

Interventional clinical trials:

(show top 50) (show all 2344)
# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
3 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
4 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
5 Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) Unknown status NCT02745132 Phase 4
6 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
7 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
8 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
9 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
10 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
11 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
12 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
13 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
14 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
15 Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
16 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
17 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
18 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
19 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
20 Endothelial Dysfunction and Subclinical Atheromatosis in Chronic HCV Infection. Response to DAA Agents. Unknown status NCT02802280 Phase 4
21 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
22 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
23 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
24 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
25 Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
26 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
27 MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV Unknown status NCT03003338 Phase 4 OBV/PTV/r and DSV;Placebo to match OBV/PTV/r and DSV
28 Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
29 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
30 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
31 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
32 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
33 Surveillance and Treatment of Prisoners With Hepatitis C Recruiting NCT02064049 Phase 4 Sofosbuvir/velpatasvir
34 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
35 Maraviroc Efficacy for Hepatitis C Recruiting NCT02881762 Phase 4 Maraviroc
36 Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients Terminated NCT01592006 Phase 4 Peginterferon alfa-2a;Ribavirin;telaprevir
37 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Not yet recruiting NCT03364725 Phase 4 Glecaprevir-pibrentasvir
38 A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment Completed NCT03212521 Phase 4 glecaprevir/pibrentasvir
39 Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients Completed NCT01469884 Phase 4 Everolimus;Cyclosporine;Tacrolimus
40 Study of Oral Treatments for Hepatitis C Active, not recruiting NCT02786537 Phase 4 sofosbuvir/ledipasvir;ombitasvir/paritaprevir/ritonavir (Phase 1 only);elbasvir/grazoprevir;Dasabuvir
41 Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation Completed NCT00821587 Phase 4 Cyclosporine;Tacrolimus
42 Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) Completed NCT02768961 Phase 4 sofosbuvir;ledipasvir
43 Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism Withdrawn NCT01415141 Phase 4 Peginterferon alfa-2a;Ribavirin;telaprevir
44 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
45 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
46 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
47 Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3 Completed NCT00143000 Phase 4 Peginterferon alfa-2a 40KD and Ribavirin
48 The SIM-SOF Trial for Hepatitis C Completed NCT02168361 Phase 4 Pegylated Interferon alfa-2b;Simeprevir;Ribavirin;Sofosbuvir
49 Australian Trial in Acute Hepatitis C Completed NCT00192569 Phase 4 Pegylated Interferon alfa 2a;Ribavirin (HIV conifected patients only)
50 Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World Completed NCT02964091 Phase 4 sofosbuvir/ledipasvir

Search NIH Clinical Center for Hepatitis C Virus

Genetic Tests for Hepatitis C Virus

Genetic tests related to Hepatitis C Virus:

# Genetic test Affiliating Genes
1 Hepatitis C Virus, Susceptibility to 29 CCR5 IFNG IFNL3 PTPRC
2 Hepatitis C Virus Infection, Response to Therapy of 29

Anatomical Context for Hepatitis C Virus

MalaCards organs/tissues related to Hepatitis C Virus:

41
Liver, T Cells, B Cells, Kidney, Testes, Bone, Thyroid

Publications for Hepatitis C Virus

Articles related to Hepatitis C Virus:

(show top 50) (show all 5768)
# Title Authors Year
1
Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. ( 30527582 )
2019
2
HIV/tuberculosis/hepatitis C virus services for incarcerated populations in Azerbaijan and the Eastern Europe Central Asia region. ( 30489347 )
2019
3
TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection. ( 30421643 )
2019
4
Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. ( 30401643 )
2019
5
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis. ( 30247174 )
2019
6
Human pegivirus isolates characterized by deep sequencing from hepatitis C virus-RNA and human immunodeficiency virus-RNA-positive blood donations, France. ( 30133782 )
2019
7
Skeletal muscle mass depletion in patients with hepatitis C virus infection. ( 30179904 )
2019
8
Quantitative detection of hepatitis C virus RNA in urine of patients with chronic hepatitis C using a novel real-time PCR assay. ( 30091789 )
2019
9
Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. ( 30024489 )
2019
10
Design and Development of Modified mRNA Encoding Core Antigen of Hepatitis C Virus: a Possible Application in Vaccine Production ( 30056690 )
2019
11
Hepatitis C virus infection in children in the era of direct-acting antiviral. ( 29962813 )
2018
12
Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population. ( 29429421 )
2018
13
Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems. ( 29972246 )
2018
14
Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers. ( 29248968 )
2018
15
Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. ( 29235977 )
2018
16
Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. ( 29438195 )
2018
17
Hepatitis C virus infection and risk of osteoporotic fracture: A systematic review and meta-analysis. ( 29322660 )
2018
18
Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. ( 29971486 )
2018
19
Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with I^-Thalassemia Major. ( 29743790 )
2018
20
HIV and hepatitis C virus infections in Quebec's provincial detention centres: comparing prevalence and related risky behaviours between 2003 and 2014-2015. ( 29981093 )
2018
21
Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single Center. ( 29962673 )
2018
22
Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages. ( 29443378 )
2018
23
Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population. ( 29446443 )
2018
24
Sofosbuvir and Ledipasvir is Associated with High Sustained Virologic Response and Improvement of Health-Related Quality of Life in East Asian Patients with Hepatitis C Virus Infection. ( 29974665 )
2018
25
Future Considerations for the Evaluation of Hepatitis C Virus Treatments in Pan-Genotypic Therapy for Noncirrhotic Treatment-Naive Patients. ( 29290175 )
2018
26
Psychiatric and functional neuroimaging abnormalities in chronic hepatitis C virus patients: Is vasculitis a contributing factor? ( 29935864 )
2018
27
Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study. ( 29438397 )
2018
28
Role of Direct-Acting Antivirals in Hepatitis C Virus-Positive Castleman Disease. ( 29557805 )
2018
29
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study. ( 29271782 )
2018
30
microRNA-122 amplifies hepatitis C virus translation by shaping the structure of the internal ribosomal entry site. ( 29973597 )
2018
31
Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. ( 29022122 )
2018
32
Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men. ( 29959866 )
2018
33
Mother-to-child transmission of hepatitis C virus. ( 29968442 )
2018
34
Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. ( 29961309 )
2018
35
Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice. ( 29437963 )
2018
36
Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried-Blood Spot Samples. ( 29959023 )
2018
37
Long-term familial Mediterranean fever remission on successful hepatitis C virus treatment in a patient not responding to colchicine: a case report. ( 29773081 )
2018
38
The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis. ( 29411135 )
2018
39
Atypical generalized morphea-like scleroderma occurring in a patient exposed to organic solvents and having chronic hepatitis C virus infection. ( 29451196 )
2018
40
Monoclonal antibodies against occludin completely prevented hepatitis C virus infection in a mouse model. ( 29437969 )
2018
41
The next wave of hepatitis C virus: The epidemic of intravenous drug use. ( 29427493 )
2018
42
Conformational Flexibility in the CD81-Binding Site of the Hepatitis C Virus Glycoprotein E2. ( 29967619 )
2018
43
Complete response of diffuse large B-cell lymphoma after direct-acting antiviral therapy for hepatitis C virus. ( 29432921 )
2018
44
Seroprevalence of hepatitis C virus among the newcomer students, Kafrelsheikh University, Egypt. ( 29981144 )
2018
45
A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan. ( 29429413 )
2018
46
Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV coinfected patients with mixed cryoglobulinemia. ( 29870852 )
2018
47
Anti-Hepatitis C Virus Activity of Uridine Derivatives of 2-Deoxy Sugars. ( 29954068 )
2018
48
Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studies. ( 29255624 )
2018
49
Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in SALo Paulo state. ( 29961118 )
2018
50
N-Myc Downstream-Regulated Gene 1 Restricts Hepatitis C Virus Propagation by Regulating Lipid Droplet Biogenesis and Viral Assembly. ( 29118118 )
2018

Variations for Hepatitis C Virus

ClinVar genetic disease variations for Hepatitis C Virus:

6 (show all 17)
# Gene Variation Type Significance SNP ID Assembly Location
1 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh37 Chromosome 3, 46414947: 46414978
2 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh38 Chromosome 3, 46373456: 46373487
3 PTPRC PTPRC, 77C-G single nucleotide variant risk factor
4 IFNG NM_000619.2(IFNG): c.-893C> G single nucleotide variant drug response rs2069707 GRCh38 Chromosome 12, 68160508: 68160508
5 IFNG NM_000619.2(IFNG): c.-893C> G single nucleotide variant drug response rs2069707 GRCh37 Chromosome 12, 68554288: 68554288
6 KRT18 NM_000224.2(KRT18): c.1230C> G (p.Thr410=) single nucleotide variant not provided rs386834225 GRCh37 Chromosome 12, 53346563: 53346563
7 KRT18 NM_000224.2(KRT18): c.1230C> G (p.Thr410=) single nucleotide variant not provided rs386834225 GRCh38 Chromosome 12, 52952779: 52952779
8 KRT18 NM_000224.2(KRT18): c.282C> T (p.Tyr94=) single nucleotide variant not provided rs386834224 GRCh37 Chromosome 12, 53343239: 53343239
9 KRT18 NM_000224.2(KRT18): c.282C> T (p.Tyr94=) single nucleotide variant not provided rs386834224 GRCh38 Chromosome 12, 52949455: 52949455
10 KRT18 NM_000224.2(KRT18): c.134G> C (p.Arg45Pro) single nucleotide variant not provided rs200221269 GRCh37 Chromosome 12, 53343091: 53343091
11 KRT18 NM_000224.2(KRT18): c.134G> C (p.Arg45Pro) single nucleotide variant not provided rs200221269 GRCh38 Chromosome 12, 52949307: 52949307
12 KRT8 NM_002273.3(KRT8): c.1033G> T (p.Ala345Ser) single nucleotide variant not provided rs386834221 GRCh37 Chromosome 12, 53292632: 53292632
13 KRT8 NM_002273.3(KRT8): c.1033G> T (p.Ala345Ser) single nucleotide variant not provided rs386834221 GRCh38 Chromosome 12, 52898848: 52898848
14 KRT8 NM_002273.3(KRT8): c.1340C> T (p.Ala447Val) single nucleotide variant not provided rs386834223 GRCh37 Chromosome 12, 53291324: 53291324
15 KRT8 NM_002273.3(KRT8): c.1340C> T (p.Ala447Val) single nucleotide variant not provided rs386834223 GRCh38 Chromosome 12, 52897540: 52897540
16 KRT8 NM_002273.3(KRT8): c.1412G> A (p.Gly471Glu) single nucleotide variant not provided rs386834222 GRCh37 Chromosome 12, 53291252: 53291252
17 KRT8 NM_002273.3(KRT8): c.1412G> A (p.Gly471Glu) single nucleotide variant not provided rs386834222 GRCh38 Chromosome 12, 52897468: 52897468

Cosmic variations for Hepatitis C Virus:

9 (show top 50) (show all 3307)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1626018 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 6
2 COSM1615665 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 6
3 COSM1602238 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 6
4 COSM6951673 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 6
5 COSM1616325 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 6
6 COSM3707827 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 6
7 COSM3707828 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 6
8 COSM1623051 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 6
9 COSM1612127 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 6
10 COSM1618451 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581L 4:145885684-145885684 6
11 COSM1611545 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 6
12 COSM1612685 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47V 19:52002156-52002156 6
13 COSM1612018 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 6
14 COSM1618219 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 6
15 COSM1624399 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 6
16 COSM1609798 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 6
17 COSM1605856 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 6
18 COSM1602404 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 6
19 COSM1607880 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221A 14:67807621-67807621 6
20 COSM3661787 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 6
21 COSM1270878 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 6
22 COSM1612900 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 6
23 COSM3663890 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 6
24 COSM6969923 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 6
25 COSM3717069 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 6
26 COSM6219678 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 6
27 COSM1613453 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 6
28 COSM3717124 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 6
29 COSM1608898 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 6
30 COSM3705381 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 6
31 COSM1601838 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 6
32 COSM1610770 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 6
33 COSM1601260 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 6
34 COSM1624206 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2136A>G p.T712T 8:80518852-80518852 6
35 COSM1624207 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2311A>G p.I771V 8:80519295-80519295 6
36 COSM1616586 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 6
37 COSM1624117 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1568A>G p.N523S 8:63187582-63187582 6
38 COSM1603361 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 6
39 COSM1617254 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167N 3:183722100-183722100 6
40 COSM3663693 XPO7 liver,NS,carcinoma,hepatocellular carcinoma c.806A>G p.Y269C 8:21977812-21977812 6
41 COSM1609152 XPO6 liver,NS,carcinoma,hepatocellular carcinoma c.882C>T p.G294G 16:28156289-28156289 6
42 COSM6957749 XPO1 liver,NS,carcinoma,hepatocellular carcinoma c.301+1G>C p.? 2:61522610-61522610 6
43 COSM1624082 XKR4 liver,NS,carcinoma,hepatocellular carcinoma c.1076A>G p.D359G 8:55523350-55523350 6
44 COSM1613650 XIRP2 liver,NS,carcinoma,hepatocellular carcinoma c.9350G>C p.R3117P 2:167250742-167250742 6
45 COSM3660541 XIRP1 liver,NS,carcinoma,hepatocellular carcinoma c.142C>A p.Q48K 3:39189304-39189304 6
46 COSM1625463 XIAP liver,NS,carcinoma,hepatocellular carcinoma c.493G>T p.A165S 23:123886155-123886155 6
47 COSM3663909 WWP1 liver,NS,carcinoma,hepatocellular carcinoma c.210-2A>G p.? 8:86381503-86381503 6
48 COSM1625309 WWC3 liver,NS,carcinoma,hepatocellular carcinoma c.1121C>A p.S374Y 23:10117180-10117180 6
49 COSM1621161 WTAP liver,NS,carcinoma,hepatocellular carcinoma c.283C>T p.Q95* 6:159748200-159748200 6
50 COSM6909096 WT1 liver,NS,carcinoma,hepatocellular carcinoma c.1019T>G p.L340* 11:32396283-32396283 6

Expression for Hepatitis C Virus

LifeMap Discovery
Genes differentially expressed in tissues of Hepatitis C Virus patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL10 chemokine (C-X-C motif) ligand 10 Liver + 4.26 0.000
2 CXCL11 chemokine (C-X-C motif) ligand 11 Liver + 3.57 0.000
3 LOC553137 uncharacterized LOC553137 Liver - 3.21 0.000
4 CXCL9 chemokine (C-X-C motif) ligand 9 Liver + 3.07 0.000
Search GEO for disease gene expression data for Hepatitis C Virus.

Pathways for Hepatitis C Virus

Pathways related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.82 CCR5 IFNG IFNL3 PTPRC
2
Show member pathways
11.65 CLDN1 CLDN6 CLDN9
3 11.42 CLDN1 CLDN6 CLDN9 PTPRC
4 11.38 CCR5 IFNG PTPRC
5 11.14 CD81 CLDN1 CLDN6 CLDN9 SCARB1

GO Terms for Hepatitis C Virus

Cellular components related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.86 ACY3 CD81 GPT KRT18 KRT8 PSMA7
2 bicellular tight junction GO:0005923 9.33 CLDN1 CLDN6 CLDN9
3 apicolateral plasma membrane GO:0016327 8.96 CLDN6 KRT8
4 cell periphery GO:0071944 8.8 KRT18 KRT8 PTPRC

Biological processes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.8 CCR5 CD81 IFNG PTPRC
2 defense response to virus GO:0051607 9.67 IFNG IFNL3 IFNL4 PTPRC
3 extrinsic apoptotic signaling pathway GO:0097191 9.5 IFNG KRT18 KRT8
4 hepatocyte apoptotic process GO:0097284 9.48 KRT18 KRT8
5 negative thymic T cell selection GO:0045060 9.46 ATG5 PTPRC
6 positive regulation of immune response GO:0050778 9.43 IFNL3 IFNL4
7 cell-cell junction organization GO:0045216 9.43 CLDN1 CLDN6 CLDN9
8 viral entry into host cell GO:0046718 9.43 CD81 CLDN1 CLDN6 CLDN9 CLEC4M SCARB1
9 regulation of phagocytosis GO:0050764 9.4 PTPRC SCARB1
10 viral process GO:0016032 9.4 ACY3 CCR5 CD81 CLDN1 CLDN6 CLDN9
11 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.33 CLDN1 CLDN6 CLDN9

Molecular functions related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.35 CLDN1 CLDN6 CLDN9 KRT18 KRT8
2 virus receptor activity GO:0001618 9.17 CCR5 CD81 CLDN1 CLDN6 CLDN9 CLEC4M
3 protein binding GO:0005515 10.06 ACY3 ATG5 CCR5 CD81 CLDN1 CLDN6

Sources for Hepatitis C Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....